Recombinant Human PILR-alpha Avi-tag His-tag Protein, CF

Recombinant Human PILR-alpha Avi-tag His-tag Protein, CF Summary

Product Specifications

Product Datasheets

Carrier Free

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

Background: PILR-alpha

PILR-alpha (paired immunoglobulin-like type 2 receptor-alpha; also FDF03) is one of two members that belong to a small family of immunoregulatory Ig-superfamily receptors (1-4). It is a counterpart to PILR-beta, and likely gave rise to the PILR-beta gene through duplication and rearrangement (1). The PILRs represent one of many pairs of Ig-like domain-containing receptors that participate in immune regulation. PILR-alpha and -beta should not be confused with the similarly named PIRs (also paired immunoglobulin-like receptors ), or the functionally-related SIRP and ILT/LILR/CD85/LIR family of receptors (2). While PIRs, ILTs and SIRPs contain three to six Ig‑like domains in their extracellular region, PILR-alpha and -beta show only one Ig-like region in their extracellular domain (ECD) (1-5). Human PILR-alpha is a monomeric, 55 kDa, 294 amino acid (aa) type I transmembrane (TM) glycoprotein (3-5). It contains a 178 aa ECD (aa 20-197), a 21 aa TM segment, and a long, 85 aa cytoplasmic region (aa 219-303). The ECD shows one V-type Ig-like domain between aa 32-150, while the cytoplasmic region contains two ITIMs (immunoreceptor Tyr-based inhibitory motifs) between aa 267-272 and 296-301. Given that ITIMs are known to interact with phosphatases such as PTPN6 and PTPN11, the presence of these motifs make mouse PILR-alpha an inhibitory receptor. Three potential isoforms for human PILR-alpha have been reported. The first contains a 24 aa substitution for aa 152‑303, a second possesses a 36 aa substitution for aa 264-303, and a third shows a deletion of aa 152-224 (6). The human PILR-alpha ECD shares 43% aa sequence identity with mouse PILR-alpha ECD, and 82% aa sequence identity with the ECD of human PILR-beta (3, 4).

PILR-alpha is expressed by neutrophils, macrophages, monocytes, mast cells, APCs, microglia, neurons, cardiac muscle and renal proximal plus pancreatic duct eipthelium (4, 7, 8). It has multiple binding partners, including CD99 (4, 9), glycoprotein B/gB of HSV-1 (7), PANP (PILR-associated neural protein) (8) and NPDC1 plus collectin-12 (10). Although PILR-alpha and -beta are related through gene duplication and highly similar in their ECD aa sequence, they do not necessarily share the same ligands (or binding partners), as PILR-beta fails to bind to gB and PANP (8, 10). Notably, PILR-alpha binding appears to be dependent upon the presence of a poorly-defined peptide sequence coupled to a sialylated, O-linked carbohydrate motif (5, 9-12). It is unclear what function(s) can be attributed to PILR-alpha. One possibility suggests that in the early stage of an immune response, PILR-beta predominates over PILR-alpha on the APC surface. Ligation of PILR-beta by CD99 induces IL-12 production and immune cell activation. But this ligation also up‑regulates PILR-alpha expression, and subsequent CD99:PILR‑ alpha engagement now promotes IL-27 production, with a concomitant increase in T cell IL-10 production, and a down‑regulation of the inflammatory response (10). Our Avi-tag Biotinylated PILR-alpha protein features biotinylation at a single site contained within the Avi-tag, a unique 15 amino acid peptide.  Protein orientation will be uniform when bound to streptavidin-coated surface due to the precise control of biotinylation and the rest of the protein is unchanged so there is no interference in the protein's bioactivity.

Related Research Areas

• Dendritic Cell ITIM/ITAM Immunoreceptors
• ITIM/ITAM Immunoreceptors and Related Molecules